Glaxosmithkline Biologicals S.A.
GlaxoSmithKline Biologicals S.A., commonly referred to as GSK Biologicals, is a leading global player in the biopharmaceutical industry, headquartered in Belgium. Founded in 1995, the company has established itself as a pioneer in vaccine development, focusing on innovative solutions to combat infectious diseases. With a strong operational presence across Europe, North America, and emerging markets, GSK Biologicals is dedicated to enhancing public health through its extensive portfolio of vaccines. The company’s core offerings include vaccines for diseases such as influenza, hepatitis, and meningitis, distinguished by their advanced research and development processes. GSK Biologicals has achieved notable milestones, including the introduction of several groundbreaking vaccines that have significantly impacted global health. As a subsidiary of GlaxoSmithKline plc, it continues to maintain a robust market position, recognised for its commitment to quality and innovation in the biopharmaceutical sector.
DitchCarbon Score
How does Glaxosmithkline Biologicals S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glaxosmithkline Biologicals S.A.'s score of 62 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Glaxosmithkline Biologicals S.A.'s reported carbon emissions
GlaxoSmithKline Biologicals S.A., headquartered in Belgium (BE), currently does not have available carbon emissions data for the most recent year. As a result, specific figures regarding their emissions in kg CO2e, including Scope 1, 2, or 3 emissions, are not provided. In the absence of detailed emissions data, it is important to note that the company has not outlined any specific reduction targets or initiatives related to carbon emissions. This lack of publicly available information on their climate commitments suggests that further transparency may be needed to understand their environmental impact and strategies for addressing climate change. As the pharmaceutical industry increasingly focuses on sustainability, GlaxoSmithKline Biologicals S.A. may benefit from establishing clear climate commitments and reduction targets to align with global efforts to mitigate climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glaxosmithkline Biologicals S.A. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
